BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q1 2022 vs. Q4 2021
How the institutions holding BIO-TECHNE Corp changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 576 | 8 | 556 | −12 |
| Shares | 37.0M | 39.4K | 37.7M | +807.6K (+2.2%) |
| Value | $19.1B | $20.4M | $16.3B | −$2.74B (−14.4%) |
8 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (65)
Institutions that held BIO-TECHNE Corp at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (77)
Institutions that held BIO-TECHNE Corp at the end of Q4 2021 and filed for Q1 2022 without it.
Not filed for Q1 2022 yet (8)
Institutions that held BIO-TECHNE Corp at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Tygh Capital Management, Inc. | 17,520 | $9.06M |
| Andra AP-fonden | 8,700 | $4.50M |
| Tdam USA Inc. | 8,304 | $4.30M |
| Ascension Asset Management LLC | 4,485 | $2.32M |
| NEXT Financial Group, Inc | 155 | $80.0K |
| Harbour Investments, Inc. | 80 | $41.0K |
| Carroll Financial Associates, Inc. | 73 | $36.0K |
| Bell Investment Advisors, Inc | 42 | $22.0K |